Long-term impact on healthcare resource utilization of statin treatment, and its cost effectiveness in the primary prevention of cardiovascular disease: A record linkage study

European Heart Journal

Volumn 35, Issue 5, 2014, Pages 290-298

  Mcconnachie, Alex ^a   Walker, Andrew ^a   Robertson, Michele ^a   Marchbank, Laura ^b   Peacock, Julie ^b   Packard, Christopher J ^c   Cobbe, Stuart M ^d   Ford, Ian ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b INFORMATION SERVICES DIVISION   (United Kingdom)

^c WESTERN INFIRMARY   (United Kingdom)

^d GLASGOW ROYAL INFIRMARY   (United Kingdom)

Author keywords

Cardiovascular outcomes; Cost effectiveness; Pravastatin; Primary prevention; Record linkage

Indexed keywords

CARDIOVASCULAR OUTCOMES; COST EFFECTIVENESS; PRAVASTATIN; PRIMARY PREVENTION; RECORD LINKAGE;

CARDIOVASCULAR DISEASES; COST-BENEFIT ANALYSIS; HEALTH RESOURCES; HOSPITALIZATION; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PRAVASTATIN; PRIMARY PREVENTION; QUALITY-ADJUSTED LIFE YEARS; STATE MEDICINE; STROKE; TREATMENT OUTCOME;

EID: 84893863909     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/eht232     Document Type: Article

References (19)

1. West of Scotland Coronary Prevention Study Group. A coronary primary prevention study of Scottish men aged 45-64 years: Trial design. J Clin Epidemiol 1992;45: 849-860.
2. TheWOSCOPS Study Group. Screening experience and baseline characteristics in the West of Scotland Coronary Prevention Study. Am J Cardiol 1995;76: 485-491.
3. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, Macfarlane PW, McKillop JH, Packard CJ. Prevention of coronary heart disease with pravastatin inmenwith hypercholesterolemia. N Engl J Med 1995;333:1301-1307.
4. Ford I, Murray H, Packard CJ, Shepherd J, Macfarlane P, Cobbe SM. Long-term follow-up of theWest of Scotland Coronary Prevention Study. N Engl J Med 2007; 357:1477-1486.
5. Caro J, KlittichW,McGuire A, Ford I, Norrie J, Pettitt D, McMurray J, Shepherd J. The West of Scotland coronary prevention study: Economic benefit analysis of primary prevention with pravastatin. BMJ 1997;315:1577-1582.
6. Taylor F,Ward K, Moore THM, Burke M, Davey Smith G, Casas JP, Ebrahim S. Statins for the primary prevention of cardiovascular disease. The Cochrane Library DOI: 10.1002/14651858.CD004816.pub4.
7. Redberg RF, Katz MH. Healthy men should not take statins. JAMA 2012;307: 1491-1492.
8. Kendrick S, Clarke J. The Scottish Record Linkage System. Health Bull 1993;51:72-79.
9. The West of Scotland Coronary Prevention Study Group. Computerised record linkage: Comparison with traditional patient follow-upmethods in clinical trials and illustrated in a prospective epidemiological study. J Clin Epidemiol 1995;48:1441-1452.
10. McLoone P, Boddy FA. Deprivation and mortality in Scotland, 1981 and 1991. BMJ 1994;309:1465-1470.
11. Scottish National Tariffs. http://isd.scot.nhs.uk/isd/6458.html
12. Joint Formulary Committee. British National Formulary. 61 ed. London: BMJ Group and Pharmaceutical Press; 2011.
13. Ward S, Lloyd-Jones M, Pandor A, Holmes M, Ara R, Ryan A, YeoW, Payne N. A systematic reviewand economic evaluation of statins for the prevention of coronary events. Health Technol Assess 2007;11.
14. Curtice L. Unit Costs of Health and Social Care 2010. Personal Social Services Research Unit, University of Kent at Canterbury (http://www.pssru.ac. uk/publication-details. php?id=131).
15. Woodward M, Brindle P, Tunstall-Pedoe H. Adding social deprivation and family history to cardiovascular risk assessment: The ASSIGN score from the Scottish Heart Health Extended Cohort (SHHEC). Heart 2007;93:172-176. doi: 10.1136/ hrt.2006.108167.
16. Conly J, Clement F, Tonelli M, Hemmelgarn SMB, Klarenbach S, Lloyd A, McAlister FA, Husereau D, Wiebe N, Au F, Manns B. for the Alberta Kidney Disease Network: Cost-effectiveness of the use of low- and high-potency statins in people at low cardiovascular risk. CMAJ 2011;183:E1185.
17. Preiss D, Seshasai SRK, Welsh P, Murphy SA, Ho JE, Waters DD, DeMicco DA, Barter P, Cannon CP, Sabatine MS, Braunwald E, Kastelein JJP, de Lemos JA, Blazing MA, Pederson TR, Tikkanen MJ, Sattar N, Ray KK. Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy a meta-Analysis. JAMA 2011;305:2556-2564.
18. Freeman DJ, Norrie J, Sattar N, Neely RDG, Cobbe SM, Ford I, Isles C, LorimerAR, Macfarlane PW,McKillop JH, PackardCJ, Shepherd J, GawA. Pravastatin and the development of diabetes mellitus: Evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study. Circulation 2001;103:357-362.
19. Cholesterol Treatment Trialists' (CTT) Collaborators. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: Meta-Analysis of individual data from 27 randomised trials. The Lancet, Early Online Publication 2012; doi:10.1016/S0140-6736(12)60367-5.